Ko-Preneliya's tablets are shown for treatment of essential hypertensia.

Structure

Active ingredients: perindoprit, indapamid.

: a perindoprila tertbutilamin – 4 mg (that corresponds to 3.338 mg of a perindopril) and indapamid – 1.25 mg; or perindoprit tertbutilamin – 8 mg (that corresponds to 6.676 mg of a perindopril) and indapamid – 2.5 mg;

Excipients: microcrystalline cellulose; lactose, monohydrate; silicon dioxide colloidal anhydrous; magnesium stearate.

Contraindication

Connected with perindoprily:

• hypersensitivity to a perindopril or to the APF any other inhibitor;
• a Quincke's disease (Quincke's edema) in the anamnesis connected with the previous treatment by APF inhibitors;
• congenital or idiopathic Quincke's disease;
• pregnancy or planning of pregnancy;
• simultaneous use with the medicaments containing aliskiren, to patients with diabetes or with a renal failure (glomerular filtration rate <60 ml/min. / 1.73 sq.m);
• simultaneous use with sakubitrilom/valsartany;
• extracorporal methods of treatment which lead to contact of blood with negatively charged surfaces;
• a considerable bilateral stenosis of renal arteries or a stenosis of an artery of the only functioning kidney.

Connected with indapamidy:

• hypersensitivity to an indapamid or to any other streptocides;
• renal failure of heavy and moderate degree (clearance of creatinine <60 ml/min.);
• hepatic encephalopathy;
• abnormal liver function of heavy degree;
• hypopotassemia;
• by the general rule, this medicine it is not necessary to appoint in a combination with not anti-arrhythmic medicaments which can cause development of Bouveret's ventricular disease like "pirouette";
• feeding period gruddyyu.

Connected with Co-preneliya drug: hypersensitivity to any excipient.

due to the lack of sufficient clinical experience of Co-preneliya should not be applied:

• to the patients who are on a hemodialysis;
• to patients with not treated dekompensirovanny heart failure.

Route of administration

For oral administration.

, a tablet of 4 mg / 1.25 mg, are shown to patients at whom arterial blood pressure respectively is not regulated by monotherapy only perindoprily. The usual dose makes 1 tablet of medicament of Co-preneliya, 4 mg / 1.25 mg a day in the form of single dosing, it is desirable in the morning before meal.

Whenever possible recommend individual titration of a dose on components.

when arterial blood pressure is not regulated by smaller doses of the combined medicaments of a perindoprila/indapamid.

in the presence of clinical indications makes the decision on direct transition from monotherapy perindoprily to reception of tablets of medicament of Co-preneliya of 4 mg / 1.25 by mg.

, a tablet of 8 mg / 2.5 mg, are shown for treatment of arterial hypertension as replacement at the patients who are already accepting perindoprit and indapamid in parallel in the same doses. The usual dose makes 1 tablet of medicament of Co-preneliya, 8 mg / 2.5 mg a day once, it is desirable in the morning before meal.

Maximum daily dose makes 1 tablet of medicament of Co-preneliya, 8 mg / 2.5 mg.

Feature of use

Pregnant

it is contraindicated to the pregnant women or women planning pregnancy to use Drug.

Children

Co-preneliya Drug should not be used for treatment of children and teenagers.

Drivers

Ability to run motor transport or to work with other mechanisms can worsen.

Overdose

Symptoms. In case of overdose the most frequent side reaction is arterial hypotension which can sometimes be followed by nausea, vomiting, spasms, dizziness, drowsiness, confusion of consciousness, an oliguria which can progress to an anury (owing to a hypovolemia) and also circulator shock. There can be disturbances of water and electrolytic balance (decrease in level of potassium and sodium in blood plasma), a renal failure, a hyperventilation, tachycardia, a cardiopalmus (palpitation), bradycardia, uneasiness, cough.

Treatment. Measures of first aid include fast removal of medicament from an organism – gastric lavage and/or intake of activated carbon, after that it is necessary to normalize water and electrolytic balance in the conditions of a hospital. In case of developing of considerable arterial hypotension the patient needs to accept horizontal position with a low headboard. In case of need it is necessary to carry out intravenous administration of isotonic solution of sodium of chloride or to apply any other way of restoration of volume of blood. Perindoprilat, the active form perindoprit, can be removed from an organism by means of a hemodialysis.

Side effects

it was Most often reported about emergence of such side reactions:

• connected with perindoprily: dizziness, a headache, paresthesias, a dysgeusia, a disorder of vision, vertigo, a ring in ears, arterial hypotension, cough, an asthma, an abdominal pain, a constipation, dyspepsia, diarrhea, nausea, vomiting, an itching, rash, myotonia and an asthenia;
• connected with indapamidy: reactions of hypersensitivity, generally dermatological, at patients with tendency to allergic and asthmatic reactions, and makulopapulezny rashes.

by

.

Lities. During simultaneous use of lithium and APF inhibitors reported about reversible increase in concentration of lithium in blood serum and increase in its toxicity. Simultaneous use of a perindopril together with indapamidy and lithium is not recommended, however if it is really necessary, it is necessary to control carefully concentration of lithium in blood serum.

Simultaneous use requiring special attention.

Baclofenum. The antihypertensive effect increases. It is necessary to control arterial blood pressure and in case of need to adjust a dose of antihypertensive drug.

Storage conditions

Tablet of 4 mg / 1.25 mg: In original packing at a temperature not above 30 °C.

out of children's reach.

Tablet of 8 mg / 2.5 mg: For medicine special storage conditions are not required.

in original packing.

out of children's reach.

Expiration date - 3 years.